Management Team
Kenneth J. Hillan, M.B. Ch.B.
Chief Executive Officer & Chief Medical Officer
Dr. Hillan joins Achaogen as Chief Medical Officer, bringing deep experience in both medicine and global drug development. Most recently, he served as Senior Vice President and Head of Roche Product Development, Asia Pacific, where he was responsible for the overall drug development strategy in the region. Prior to that, he held a variety of positions at Genentech (acquired by Roche in 2009) including Senior Vice President Clinical Development, Inflammation, Vice President Research Operations and Pathology, Vice President, Development Sciences, and Vice President Immunology, Tissue Growth and Repair (ITGR). While there, he also served in executive leadership roles as Chair, Roche: Chugai Development Committee and Member, Roche: Chugai Joint Commercial Committee, Head, Roche Inflammation Disease Biology Leadership Team (Research through Commercial), Member, Roche Personalized Healthcare Steering Committee, Co-Chair, Genentech’s Late-Stage Portfolio Committee, Executive Sponsor and Chair, Development Review Committee, Member, Genentech Research Review Committee, Member, Genentech Healthcare Compliance Committee, and Member, Genentech Product Safety Committee. Dr. Hillan has also authored dozens of scientific publications and is a named inventor on almost 50 issued patents.
He holds an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, is a Fellow of the Royal College of Surgeons (FRCS), and a Fellow of the Royal College of Pathologists (FRCPath). He also serves as Honorary Professor of Molecular and Therapeutic Pathology at the University of Leeds.
John C. Doyle
Chief Operating Officer
Mr. Doyle joined Achaogen in August 2009. His responsibilities at the Company include finance, technical operations, information technology, R&D project management, and investor relations. Previously, Mr. Doyle was with Genentech (acquired by Roche), where he served as Vice President of Finance and Corporate Planning. Prior to Genentech, he was Chief Financial Officer and Senior Vice President of Corporate Development at Renovis Inc. (acquired by Evotec AG), a publicly-held biopharmaceutical company focused on neurological diseases and disorders. Mr. Doyle has also held finance-related positions at Tularik Inc. (acquired by Amgen) and PricewaterhouseCoopers.
Mr. Doyle received an M.B.A. from U.C. Berkeley, and a B.S. from Cal Poly, San Luis Obispo.
Becki Filice
Vice President, Development Operations and Portfolio Management
Ms. Filice joined Achaogen in 2011 as Vice President, Development Operations and Portfolio Management. In her current role, she has responsibilities for Development Sciences, Clinical Operations, Biometrics, and Project Management. She also serves as Project Team Leader for ACHN-975. Prior to joining Achaogen, Ms. Filice was at Genentech (acquired by Roche in 2009), holding a variety of positions, most recently as Sr. Director of Project Excellence. Her background includes leadership roles in Clinical Data Management, Clinical Operations, Project Management, Resource Management, and Project Team Leader positions for Avastin® and Nutropin®. Becki also held management positions with Ligand Pharmaceuticals, and Syntex, Inc. She started her career as a Clinical Microbiologist at El Camino Hospital in Mountain View, California.
Ms. Filice holds a Bachelor’s Degree in Microbiology from University of California at Davis, and an MBA from Santa Clara University.
John F. Hollway
VP, Business Development
John manages Achaogen's business development, strategic marketing, and legal activities, including in particular its non-dilutive financing strategies and its relationships with government agencies. Prior to joining Achaogen, John was the Vice President of Operations, Strategy & Corporate Development, and Chief Privacy Officer for Acurian, Inc., a clinical services company. There he built Acurian’s clinical data services and was responsible for the overall management of client projects and the establishment and maintenance of industry-leading data management standards and procedures. John was the General Manager in charge of wireless strategy and product development for Shared Medical Systems Corp, now Siemens Medical Systems (SMS). Prior to his business career, he was an attorney at Morgan, Lewis & Bockius LLP. He holds a J.D. with honors from the George Washington University Law School, and a B.A. from the University of Pennsylvania.
